TaiRx, Inc.
6580
Rank in Stocks
#23876
TaiRx, Inc., established in 2011 and headquartered in Taipei City, Taiwan, is a... TaiRx, Inc., established in 2011 and headquartered in Taipei City, Taiwan, is a pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for cancer and other diseases. The company's clinical pipeline includes CVM-1118, an oral anti-cancer drug currently undergoing Phase II clinical trials, and Rexis, an add-on injection therapy for sepsis patients, which is in Phase III trials. In its pre-clinical stage, TaiRx is developing TRX-711 for secondary hyperparathyroidism, TRX-920 as an oral delivery formulation, and TRX-105, a molecule designed to treat and alleviate symptoms of various types of colitis. Beyond its developmental drugs, TaiRx also offers Zelnite, a medication that helps maintain patients' blood selenium levels and supports their immune systems. The company's future endeavors also involve the development of nodal diagnostic devices and innovative antibody-based drugs.
Share Price
$0.33837749
Last synced: 2026-11-10
Market Cap
$37.94M
Change (1 day)
0.00%
Change (1 year)
-55.28%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade TaiRx, Inc. (6580)
Category
Healthcare
Operating Margin for TaiRx, Inc. (6580)
Operating Margin as of November 2026 TTM: -834.73%
According to TaiRx, Inc.'s latest financial reports, its current operating margin (TTM) is -834.73%. At the end of 2025 the company had an operating margin of -851.50%.
Operating Margin history for TaiRx, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -834.73% | -1.97% |
| 2025 | -851.50% | -52.04% |
| 2024 | -1,775.29% | -57.98% |
| 2023 | -4,224.62% | 37.26% |
| 2022 | -3,077.89% | 21.55% |
| 2021 | -2,532.23% | -47.82% |
| 2020 | -4,853.29% | -6.17% |
| 2019 | -5,172.56% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.05% |
US
|
|
| -149.01% | -99.82% |
US
|
|
| 25.57% | -100.03% |
AU
|
|
| 31.23% | -100.04% |
BE
|
|
| 29.35% | -100.04% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about TaiRx, Inc.'s operating margin
What is TaiRx, Inc.'s operating margin?
TaiRx, Inc.'s operating margin is -834.73%, as of Nov 2026.
What was TaiRx, Inc.'s operating margin in 2025?
In 2025, TaiRx, Inc.'s operating margin was -851.50%, compared with -1,775.29% in 2024.
How has TaiRx, Inc.'s operating margin changed since 2020?
From 2020 to 2025, TaiRx, Inc.'s operating margin was highest in 2025 (-851.50%) and lowest in 2020 (-4,853.29%).
How does TaiRx, Inc.'s operating margin compare with similar companies?
TaiRx, Inc.'s operating margin (-834.73%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.